MA54719A - Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines - Google Patents
Composition pharmaceutique pour réduire les toxines urémiques liées aux protéinesInfo
- Publication number
- MA54719A MA54719A MA054719A MA54719A MA54719A MA 54719 A MA54719 A MA 54719A MA 054719 A MA054719 A MA 054719A MA 54719 A MA54719 A MA 54719A MA 54719 A MA54719 A MA 54719A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- uremic toxins
- reducing protein
- bound uremic
- bound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002441 uremic toxin Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021003641 | 2020-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54719A true MA54719A (fr) | 2021-11-17 |
Family
ID=74661416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054719A MA54719A (fr) | 2020-01-27 | 2021-01-25 | Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12048713B2 (fr) |
| EP (1) | EP3908260B1 (fr) |
| AU (1) | AU2021214954B2 (fr) |
| CA (1) | CA3130438C (fr) |
| CO (1) | CO2021016583A2 (fr) |
| MA (1) | MA54719A (fr) |
| PE (1) | PE20221660A1 (fr) |
| PH (1) | PH12021552416A1 (fr) |
| UA (1) | UA128706C2 (fr) |
| WO (1) | WO2021152441A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0101459D0 (en) * | 2001-01-19 | 2001-03-07 | Uni Vite Exp Ltd | Nutritional composition |
| CN1504229A (zh) | 2002-12-05 | 2004-06-16 | 王永山 | 治疗慢肾衰、尿毒症的免疫排毒粉 |
| FR2851425A1 (fr) * | 2003-02-21 | 2004-08-27 | Oligocaps Lab | Complement nutritionnel a base de chitosan ayant une composition original sous diverses formes galeniques |
| US7198785B2 (en) | 2003-12-09 | 2007-04-03 | Brown University | Systems and methods related to degradation of uremic toxins |
| TWI481409B (zh) | 2013-01-10 | 2015-04-21 | Conmed Pharmaceutical & Bio Medical Corp | 一種使用益生菌製備用於清除尿毒素之組合物的用途 |
| MX367504B (es) | 2013-03-21 | 2019-07-31 | Nutrimentos Inteligentes S A De C V | Mezcla gelatinosa de probióticos y prebióticos con acción simbiótica sinérgica para el tratamiento de enfermedad renal crónica. |
| CN104740611B (zh) | 2015-04-13 | 2017-04-12 | 江西康宝医药生物科技有限公司 | 一种治疗尿毒症的中药组合物及其制备方法 |
| WO2018125693A1 (fr) * | 2016-12-27 | 2018-07-05 | Hill's Pet Nutrition, Inc. | Compositions alimentaires pour animaux de compagnie et méthodes associées |
| CA3067991A1 (fr) * | 2017-06-26 | 2019-01-03 | Kibow Biotech, Inc. | Procedes de maintien et d'amelioration de la fonction renale chez des patients atteints d'une maladie renale et suivant une therapie de soins standard |
-
2021
- 2021-01-25 PE PE2021002016A patent/PE20221660A1/es unknown
- 2021-01-25 CA CA3130438A patent/CA3130438C/fr active Active
- 2021-01-25 UA UAA202105402A patent/UA128706C2/uk unknown
- 2021-01-25 PH PH1/2021/552416A patent/PH12021552416A1/en unknown
- 2021-01-25 EP EP21706030.0A patent/EP3908260B1/fr active Active
- 2021-01-25 WO PCT/IB2021/050538 patent/WO2021152441A1/fr not_active Ceased
- 2021-01-25 US US17/435,222 patent/US12048713B2/en active Active
- 2021-01-25 AU AU2021214954A patent/AU2021214954B2/en active Active
- 2021-01-25 MA MA054719A patent/MA54719A/fr unknown
- 2021-12-06 CO CONC2021/0016583A patent/CO2021016583A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021214954A1 (en) | 2021-09-02 |
| CA3130438A1 (fr) | 2021-08-05 |
| AU2021214954B2 (en) | 2023-06-29 |
| US20220370492A1 (en) | 2022-11-24 |
| EP3908260B1 (fr) | 2022-09-21 |
| CA3130438C (fr) | 2023-08-01 |
| WO2021152441A1 (fr) | 2021-08-05 |
| PH12021552416A1 (en) | 2022-07-11 |
| EP3908260A1 (fr) | 2021-11-17 |
| CO2021016583A2 (es) | 2022-01-17 |
| US12048713B2 (en) | 2024-07-30 |
| PE20221660A1 (es) | 2022-10-26 |
| UA128706C2 (uk) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| EP3549588A4 (fr) | Composition pharmaceutique pour prévenir ou traiter le cancer du foie, comprenant un polymorphe cristallin d'hexaoxyde de tétra-arsenic | |
| EP3849643A4 (fr) | Joint nasal pour interface patient respiratoire | |
| BR112022014306A2 (pt) | Anticorpo anti-angptl3 e uso do mesmo | |
| EP4153285A4 (fr) | Casque pour interface patient | |
| GB202213827D0 (en) | Ue initiated model-updates for two-sided ai/ml model | |
| MA54719A (fr) | Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines | |
| EP3708173A4 (fr) | COMPOSITION PHARMACEUTIQUE THÉRAPEUTIQUE POUR LE CANCER COMPRENANT UN miARN | |
| IL282091A (en) | System and method for removing uremic toxins from a patient's body | |
| SG11202102616PA (en) | Method and composition for removing uremic toxins | |
| IL287392A (en) | New compounds and their pharmaceutical preparations for the treatment of kidney diseases | |
| EP3743072A4 (fr) | Composition pharmaceutique pour administration à libération prolongée de buprénorphine | |
| EP4144371A4 (fr) | Médicament combiné pour le traitement du cancer du rein | |
| EP4349349A4 (fr) | Composition pharmaceutique contenant des fibroblastes pour le traitement d'une maladie rénale | |
| EP3881856A4 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
| AU2022214501A9 (en) | Pharmaceutical composition for treating liver diseases using ssu72 | |
| EP4174087A4 (fr) | Médicament pour le traitement de tumeur | |
| EP4130025A4 (fr) | Composition comprenant un peptide vgll1 pour le traitement du cancer | |
| IL304221A (en) | A method for treating chronic kidney diseases | |
| EP3958972A4 (fr) | Médicament thérapeutique pour la dyskinésie | |
| EP3897602A4 (fr) | Associations pharmaceutiques pour le traitement du cancer | |
| EP4531768A4 (fr) | Châssis pour corps supérieur | |
| EP4190340A4 (fr) | Médicament thérapeutique ou médicament de diagnostic pour le cancer | |
| HK40117095A (en) | Methods for treating anemia of kidney disease | |
| FR2875404B1 (fr) | Composition pharmaceutique pour le traitement de la rosacee |